Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage III N2 Non-Small Cell Lung Cancer: Primary Results from SQUAT trial (WJOG 12119L)
- Published on 04/15/2025
- Reading time: 4 min.
Hamada, Akira; Soh, Junichi; Hata, Akito; Nakamatsu, Kiyoshi; Shimokawa, Mototsugu; Yatabe, Yasushi; Suzuki, Jun; Tsuboi, Masahiro; Horinouchi, Hidehito; Sakairi, Yuichi; Tanahashi, Masayuki; Toyooka, Shinichi; Okada, Morihito; Matsuura, Natusmi; Shigematsu, Hisayuki; Nishimura, Yasumasa; Yamamoto, Nobuyuki; Nakagawa, Kazuhiko; Mitsudomi, Tetsuya.
Résumé
Introduction
Neoadjuvant chemo-immunotherapy is one of the standard treatment options for resectable stage II-III non-small cell lung cancer (NSCLC). However, this treatment yielded insufficient local control in the CheckMate 816 trial. We hypothesized that adding radiotherapy could improve local control, thereby improving survival outcomes.
Methods Eligible patients had clinical T1–3/T4 (tumor size) N2 stage IIIA–B...
To continue reading this article in Full-Text...
Peer-Reviewed Journals A-Z
Search | Advanced search
Get the latest news in Oncology
Receive our newsletter to stay up to date with the latest news in Oncology
